TRINTELLIX Drug Patent Profile

Which patents cover Trintellix, and when can generic versions of Trintellix launch?

Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventeen patent family members in forty-two countries.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Trintellix

Trintellix was eligible for patent challenges on September 30, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 30, 2031. This may change due to patent challenges or generic licensing.

There have been twenty-four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are three tentative approvals for the generic drug (vortioxetine hydrobromide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for TRINTELLIX

International Patents:	217
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	11
Patent Applications:	223
Drug Prices:	Drug price information for TRINTELLIX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRINTELLIX
What excipients (inactive ingredients) are in TRINTELLIX?	TRINTELLIX excipients list
DailyMed Link:	TRINTELLIX at DailyMed

See drug prices for TRINTELLIX

See drug sales revenues for TRINTELLIX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRINTELLIX

NDA:

204447

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRINTELLIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seasons Biotechnology (Taizhou) Co., Ltd.	Phase 1
H. Lundbeck A/S	Phase 3
Todd Doyle	Phase 4

See all TRINTELLIX clinical trials

Paragraph IV (Patent) Challenges for TRINTELLIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRINTELLIX	Tablets	vortioxetine hydrobromide	5 mg, 10 mg, 15 mg and 20 mg	204447	15	2017-10-02

US Patents and Regulatory Information for TRINTELLIX

TRINTELLIX is protected by ten US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No					Y

Expired US Patents for TRINTELLIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-001	Sep 30, 2013
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-002	Sep 30, 2013
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013

International Patents for TRINTELLIX

When does loss-of-exclusivity occur for TRINTELLIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Austria

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Germany

Hong Kong

Israel

Japan

Malaysia

Mexico

Morocco

New Zealand

Norway

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRINTELLIX around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2431039
Spain	2355434
Eurasian Patent Organization	015287	1-[2-(2,4-ДИМЕТИЛФЕНИЛСУЛЬФАНИЛ)ФЕНИЛ]ПИПЕРАЗИН В КАЧЕСТВЕ СОЕДИНЕНИЯ С СОЧЕТАНИЕМ АКТИВНОСТИ В ОТНОШЕНИИ ПОВТОРНОГО ЗАХВАТА СЕРОТОНИНА, 5-НТИ 5-НТДЛЯ ЛЕЧЕНИЯ КОГНИТИВНОГО НАРУШЕНИЯ (1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HTAND 5-HTACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT)
Egypt	25095	Phenyl-piperazines derivatives as serotonin reuptake inhibitors.
China	101636161

Supplementary Protection Certificates for TRINTELLIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1436271	132014902248131	Italy		PRODUCT NAME: VORTIOXETINA O UN SUO SALE DI ADDIZIONE CON UN ACIDO FARMACEUTICAMENTE ACCETTABILE(BRINTELLIX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/891/001-2-3-4-5-6-7, 20131218
1436271	1490023-7	Sweden		PRODUCT NAME: VORTIOXETINE ELLER ETT FARMACEUTISKT GODTAGBART SYRAADDITIONSSALT DAERAV; REG. NO/DATE: EU/1/13/891 20131218
1436271	300652	Netherlands		PRODUCT NAME: VORTIOXETINE OF EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT ERVAN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218
1436271	C01436271/01	Switzerland		PRODUCT NAME: VORTIOXETINE; REGISTRATION NO/DATE: SWISSMEDIC 65937 09.06.2016
1436271	2014/022	Ireland		PRODUCT NAME: VORTIOXETINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/891 20131220

Market Dynamics and Financial Trajectory of TRINTELLIX (Vortioxetine)

Last updated: March 1, 2026

TRINTELLIX (vortioxetine) is an antidepressant approved by the U.S. Food and Drug Administration in 2013 for major depressive disorder (MDD). It belongs to the serotonin modulators and stimulators class, targeting multiple serotonin receptors. Its market performance and financial trajectory are driven by prescription trends, competitive landscape, regulatory factors, and evolving treatment guidelines.

Market Size and Growth Drivers

The global antidepressant market was valued at approximately USD 14 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 2.5% from 2023 to 2030, reaching USD 17 billion. This growth is primarily driven by increasing prevalence of depression and broader acceptance of newer agents like TRINTELLIX.

Key Market Segments

Segment	Market Share (2022)	Growth Drivers
Major depressive disorder	65%	Rising diagnosis rates, increased awareness
Generalized anxiety disorder	20%	Expanded indications, off-label use
Other depression types	15%	Off-label prescribing, comorbid condition management

The antidepressant market is dominated by selective serotonin reuptake inhibitors (SSRIs) like sertraline and escitalopram, but vortioxetine has differentiated itself through improved cognitive outcomes and tolerability.

Sales and Revenue Trends

In 2022, global sales of TRINTELLIX were estimated at USD 950 million. The U.S. accounted for roughly 70% of sales, driven by high prescription volume. Outside the U.S., markets such as Europe and Japan contributed USD 180 million and USD 50 million, respectively.

Historical Sales Data

Year	Estimated Global Sales (USD million)	U.S. Sales (% of global)
2018	700	65%
2019	800	70%
2020	850	72%
2021	900	72%
2022	950	70%

Sales growth reflects increased adoption, especially as physicians prefer it for patients intolerant to SSRIs or with cognitive impairment.

Competitive Landscape

TRINTELLIX competes with several antidepressants, including:

• SSRIs: sertraline, escitalopram
• SNRIs: venlafaxine, duloxetine
• Atypical antidepressants: bupropion, mirtazapine
• Other novel agents: esketamine, vilazodone

Key differentiators for vortioxetine include its multimodal serotonin activity and cognitive benefits observed in clinical trials. Its side effect profile favors tolerability over some competitors.

Market Share and Positioning

Drug	Estimated Market Share (2022)	Differentiation
Sertraline	30%	Cost-efficient, well-established
Escitalopram	20%	Favorable side effects
TRINTELLIX	8%	Cognitive effects, tolerability
Others	42%	Varied

Despite a smaller market share, TRINTELLIX maintains a niche among physicians seeking alternatives for resistant depression.

Regulatory and Labeling Factors

TRINTELLIX's approval includes indications for MDD; ongoing studies aim to expand into pediatric depression and anxiety disorders. These studies could influence prescribing patterns.

Label updates in 2021 emphasized its cognitive benefits, further differentiating it from SSRIs. No significant safety issues or regulatory hurdles have arisen recently.

Price and Reimbursement Trends

Average wholesale price (AWP) for TRINTELLIX stands at approximately USD 10 per pill. Payers favor formulary inclusion for agents demonstrating improved compliance due to fewer side effects.

Reimbursement rates have remained stable, with supplemental coverage in major markets. Price competition remains mild, with generics delayed until 2027 in key markets.

Patent and Patent Litigation

The primary patent protecting TRINTELLIX expired in 2022. The company has filed new patents on formulations and methods of use that could extend market exclusivity until 2030. Patent litigation from generics remains ongoing.

Future Outlook

Prescription volumes are expected to increase modestly, shaped by:

• Growing awareness of cognitive deficits in depression
• Expansion into new territories and precision medicine approaches
• Competitive pressure from generics post-patent expiry

Sales are projected to stabilize at approximately USD 1 billion globally by 2025, assuming no significant market disruptions.

Risk Factors

• Patent expiration reducing exclusivity
• Competition from new therapeutic modalities, including ketamine and digital therapeutics
• Regulatory shifts impacting labeling or approvals

---

Key Takeaways

• TRINTELLIX generated USD 950 million globally in 2022, with the U.S. leading sales.
• Growth driven by increased recognition of cognitive benefits and tolerability.
• Competition from established SSRIs and generics will pressure pricing and market share.
• Patent protections extend safely into the late 2020s, maintaining market exclusivity.
• Overall market growth is moderate, with sales stabilization anticipated post-2025.

---

FAQs

1. When will generic vortioxetine become available?
Generic versions are expected after patent expiry, which is scheduled for 2027 in major markets.

2. How does TRINTELLIX compare to SSRIs in efficacy?
Clinical trials suggest TRINTELLIX offers comparable antidepressant efficacy with added cognitive benefits and a favorable side-effect profile.

3. What are the main barriers to market growth for TRINTELLIX?
Patent expiration, competitive pricing, and emergence of newer therapies like ketamine and digital platforms.

4. Are there ongoing studies to expand TRINTELLIX’s indications?
Yes, studies are underway for pediatric depression and other anxiety disorders.

5. How has reimbursement affected TRINTELLIX sales?
Reimbursement policies support its formulary access; however, payer pressure has limited price increases and is subject to regional variation.

---

References

1. IQVIA (2023). Global Prescription Drug Market Report.
2. EvaluatePharma (2022). Antidepressant Market Share Analysis.
3. U.S. FDA (2013). Approval Document for TRINTELLIX.
4. MarketWatch (2023). Antidepressant Market Trends.
5. PatentScope (2023). Vortioxetine Patent Timeline.